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The immune cell transcription factor T-bet
A novel metabolic regulator
Emilie Stolarczyk1, Graham M Lord2, and Jane K Howard1,*
1Division of Diabetes and Nutritional Sciences; Department of Experimental Immunobiology; King’s College London; London, UK;  
2Department of Experimental Immunobiology; King’s College London; London, UK
Obesity-associated insulin resistance is accompanied by an alteration in 
the Th1/Th2 balance in adipose tissue. 
T-bet (Tbx21) is an immune cell tran-
scription factor originally described as 
the master regulator of Th1 cell develop-
ment, although is now recognized to have 
a role in both the adaptive and innate 
immune systems. T-bet also directs 
T-cell homing to pro-inflammatory sites 
by the regulation of CXCR3 expression. 
T-bet−/− mice have increased visceral adi-
posity but are more insulin-sensitive, 
exhibiting reduced immune cell content 
and cytokine secretion specifically in the 
visceral fat depot, perhaps due to altered 
T-cell trafficking. Studies of T-bet defi-
ciency on Rag2- and IFN-γ-deficient 
backgrounds indicate the importance of 
CD4+ T cells and IFN-γ in this model. 
This favorable metabolic phenotype, 
uncoupling adiposity from insulin resis-
tance, is present in young lean mice yet 
persists with age and increasing obesity. 
We suggest a novel role for T-bet in meta-
bolic regulation.
The close association between nutri-
ent excess and alterations in the cellular 
and molecular mediators of inflamma-
tion and immunity is being increasingly 
appreciated. This is particularly evident 
in the development of obesity and insulin 
resistance. Insulin resistance is a major 
pathological feature of obesity, type 2 dia-
betes, and cardiovascular disease, causes 
of considerable morbidity and mortality 
worldwide. Multiple factors are thought 
to contribute to systemic insulin resis-
tance, and work over the past decade has 
highlighted the role of chronic inflam-
mation in visceral adipose tissue as a key 
component and promoter of this condi-
tion.1-3 Most early studies examined the 
role of adipose tissue macrophages in obe-
sity-associated insulin resistance, but there 
is mounting evidence for a key role of the 
adaptive immune system, particularly 
T cells, in this process.4-7 We have recently 
described a novel role for the immune 
cell transcription factor, T-bet (Tbx21) 
in immunometabolism.8 Mice deficient 
for T-bet display greater visceral fat but 
are paradoxically more insulin-sensitive 
(Fig. 1). Here, we discuss the unusual 
metabolic phenotype of the T-bet-deficient 
mouse and how the absence of T-bet might 
uncouple obesity and insulin resistance as 
part of an emerging role for T-bet in meta-
bolic physiology and pathophysiology.
The immune and endocrine systems 
are functionally and anatomically inte-
grated. We were the first to report that 
the adipocyte-derived hormone leptin, a 
key regulator of food intake and energy 
homeostasis, is also an important immune-
modulatory cytokine linking nutritional 
status with immune function.9,10 Adipose 
tissue is now recognized to be complex; 
it comprises not only mature adipocytes, 
but also preadipocytes, endothelial cells, 
and immune cells in the stromal vascular 
fraction. Humoral mediators (adipokines) 
released from adipose tissue affect whole 
body energy homeostasis. Immune cells 
are present in normal lean adipose tissue 
prior to the onset of obesity, but increasing 
adiposity is accompanied by significant 
changes in the immune cell populations 
within fat. This alteration of immune 
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cell populations in obesity is thought to 
lead to the adverse metabolic complica-
tions of obesity through the liberation 
of pro-inflammatory cytokines, such as 
interleukin (IL)-1 (IL-1), IL-6, and tumor 
necrosis factor-α (TNF-α).2,3,11
Alteration in the balance between dif-
ferent T-cell populations within visceral 
adipose tissue in particular appears to be 
an early event in obesity. Defined largely 
by their secreted cytokine profile, CD4+ 
T cells lineages include T helper (Th) 
1, Th2, and Th17, and regulatory T cell 
(Treg) subsets.12 It is now over a decade 
since we first reported that the adipocyte-
derived hormone leptin, which is increased 
in obesity, is able to influence T-cell devel-
opment and survival10 and modulate the 
T-cell immune response by enhancing 
T-cell proliferation and inducing the pro-
duction of pro-inflammatory cytokines 
such as interferon-γ (IFN-γ).9,13 Indeed, 
we found that leptin was able to alter the 
balance between Th1 and Th2 immune 
responses skewing toward a Th1 pheno-
type and suppressing Th2 responses.9,13 
As with other chronic inflammatory con-
ditions like atherosclerosis, the Th1/Th2 
balance is now recognized to be altered in 
obesity.14,15 Obesity is thought to skew T 
cells toward a Th1 or pro-inflammatory 
phenotype in fat and this is associated 
with the development of insulin resis-
tance. In obesity, the T cell population 
in adipose tissue changes: there is a sig-
nificant increase in pro-inflammatory 
Th1 cell numbers but also a reduction in 
the proportion of Foxp3+ Tregs.5,6,15 The 
observed recruitment to, and expansion 
of, adipose tissue Th1 cells and decline 
in Tregs has been reported in both obese 
mice and humans.16 Interestingly, as well 
as promoting this Th1 bias,9 leptin has 
more recently been found to have a nega-
tive effect on the proliferative capacity of 
Tregs.17 IFN-γ, the signature pro-inflam-
matory cytokine secreted by Th1 cells, 
is a strong activator of macrophages. In 
contrast, Foxp3+ Tregs are thought to 
exert anti-inflammatory effects in adipose 
tissue.5,6 IL-10 is an anti-inflammatory 
cytokine produced by Tregs and can pro-
tect adipocytes from the negative effects 
on insulin signaling induced by TNF-α.18 
Thus in obesity, there are alterations in 
adipose tissue immune cell populations, 
which regulate the inflammatory environ-
ment; this impacts on energy balance and 
glucose homeostasis.
Several recent studies have reported 
that T cells influence glucose homeosta-
sis in mice with diet induced obesity.5-7,15 
T-bet (Tbx21) is a member of the T-box 
transcription factor family member and 
regulates the differentiation and func-
tion of immune cells.19-21 Expression of 
T-bet is almost exclusively restricted to 
the immune system, although its expres-
sion in the olfactory bulb has been 
reported its functional role in this loca-
tion is unclear.22,23 T-bet is best known, 
and was originally described, for its role in 
the development of Th1 cells, where it is 
directly responsible for the transactivation 
of the signature Th1 cytokine, IFN-γ.19 
Given the recognition of altered Th1/Th2 
balance in obesity-associated insulin resis-
tance, it was therefore not surprising that 
we found T-bet-deficient mice were more 
insulin-sensitive than wild-type (WT) 
control mice.8 We also observed, however, 
than T-bet deficiency was associated with 
a modest increase in visceral adiposity. As 
increased visceral adipose tissue mass is 
usually associated with worsening insulin 
sensitivity rather than improved insulin 
sensitivity;24 this finding was unusual. 
Furthermore, the dissociated phenotype 
of increased visceral adiposity and bet-
ter insulin sensitivity was not restricted 
to mice following high fat diet feeding, 
but was also present in mice as young as 
8 weeks old, suggesting a role for T-bet in 
metabolic physiology.
So why are T-bet-deficient mice fatter 
than WT mice? The answer to this seem-
ingly simple question is not so clear. We 
found that despite being heavier, the food 
intake of T-bet−/− mice was not greater 
and was, in fact, cumulatively slightly 
less than that observed in wild-type 
mice. Energy expenditure was, however, 
significantly less in T-bet-deficient mice 
and this appeared to be in part due to 
reduced physical activity. The mechanism 
for this intriguing observation remains 
unknown, but is unlikely to be due to a 
direct central effect, given T-bet’s near 
exclusive immune-restricted expression. 
Increased adiposity has been reported 
without adverse metabolic effects in the 
context of transgenic overexpression of 
adiponectin in the obese, leptin-deficient 
ob/ob mouse.25 It is possible that T-bet 
may interact with peroxisome prolifera-
tor-activated receptor gamma (PPAR-γ) 
signaling pathways. PPAR-γ is a key 
molecular mediator of both adipogenesis 
and insulin sensitivity.26 PPAR-γ agonists, 
such as pioglitazone, which are used as 
insulin sensitizing agents in the treatment 
of type 2 diabetes, also increase adiponec-
tin levels25,27,28 and are associated with a 
concomitant increase in fat mass. These 
models however, differ from T-bet defi-
ciency as their improved insulin sensitivity 
Figure  1. t-bet deficiency uncouples visceral adiposity from insulin resistance. t-bet-deficient 
mice have fewer immune cells and altered cytokine secretion in visceral fat compared with wild-
type mice both in young chow-fed mice and following high fat diet feeding. Despite an increase in 
visceral fat mass with higher circulating leptin, T-bet−/− mice displayed enhanced systemic insulin 
sensitivity.
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is accompanied by the expansion of the 
subcutaneous adipose depot but a reduc-
tion in mass of the visceral adipose tissue 
depot, rather than a significant increase in 
visceral adipose tissue mass as observed 
in the T-bet-deficient mouse. Interest-
ingly, PPAR-γ expressed in visceral adi-
pose tissue Tregs has recently been found 
to contribute substantially to the insulin 
sensitizing effect of pioglitazone as well as 
the upregulation of several genes involved 
in lipid metabolism.29 The role of PPAR-γ 
and its downstream signaling pathways in 
the adipose and metabolic phenotype of 
T-bet deficiency therefore warrants fur-
ther investigation.
Recent years has seen the role of T-bet 
in the regulation and function of immune 
cells broaden from one where it was seen 
primarily as the master regulator of Th1 
cell development, to one which involves 
multiple cells types of both the adaptive 
and innate immune systems.30-33 Indeed, 
a wide range of immune cell types from 
both the adaptive and innate immune sys-
tem have been implicated in obesity asso-
ciated adipose tissue inflammation and 
insulin resistance.5,6,34-36 The potential 
role of T-bet in the adaptive and innate 
immune system in this process was dis-
sected by studies in Rag2-deficient mice 
which lack an adaptive immune sys-
tem (B, T, and NKT cells). The similar 
body weight, fat distribution, and glu-
cose homeostasis phenotype we found for 
T-bet-deficient mice on a Rag2-deficient 
background (Rag2−/− × T-bet−/−) and Rag2-
deficient mice suggested, however, that it 
is T-bet expression in the adaptive immune 
system rather than in the innate immune 
system that is of prime importance to the 
favorable metabolic phenotype observed 
T-bet deficiency. Indeed, adoptive trans-
fer of T-bet-deficient CD4+ T cells to a 
Rag2-deficient host resulted in a modest 
improvement of insulin sensitivity.
In fat, resident T cells have been found 
to be highly polarized to a Th1 pheno-
type with high expression of both T-bet 
and IFN-γ.6 The role of the signature 
Th1 cytokine, IFN-γ in the favorable 
metabolic phenotype of T-bet−/− mice was 
addressed by studies in IFN-γ-deficient 
mice. Deficiency of IFN-γ has been 
reported to improve glucose homeosta-
sis in obesity, although there have been 
conflicting reports on its effect on adi-
posity.37-39 Production of IFN-γ, unlike 
T-bet, is not immune restricted and the 
relationship between the two is not a 
simple one: IFN-γ is both upstream and 
downstream of T-bet and not all effects 
of IFN-γ are T-bet-dependent and vice 
versa.20,40 In fact, the phenotypes of T-bet 
and IFN-γ deficiency are immunologi-
cally distinct.41,42 However, as we found 
that loss of T-bet on an IFN-γ-deficient 
background did not confer any additional 
metabolic benefit, it is likely that the 
improved glucose homeostasis observed 
in T-bet deficiency is IFN-γ-dependent. 
We also demonstrated that mice lacking 
T-bet on a Rag2-deficient background 
had significantly diminished IFN-γ levels 
(likely due to the marked T-bet-dependent 
reduction in NK cells) yet exhibited simi-
lar metabolic phenotype to Rag2-deficient 
mice that still expressed T-bet in cells of 
the innate immune system.8 These data 
are consistent with the emerging impor-
tance of adaptive immunity in immuno-
metabolism and, together with the studies 
in IFN-γ-deficient mice, suggest that 
IFN-γ from the innate immune system is 
less important than that originating from 
cells of the adaptive immune system in the 
metabolic phenotype of these models.
T-bet−/− mice displayed a reduction of 
the immune cell content in the visceral fat 
depot specifically. In contrast, immune cell 
populations were similar in the subcutane-
ous fat depot as well as in muscle (unpub-
lished observations). The only exception to 
these depot specific differences in immune 
cell content was the expected significant 
reduction of the natural killer (NK) cell 
population; NK cells are developmentally 
dependent on T-bet33,43 and were found to 
be lower in all tissues examined. The vis-
ceral depot specific reduction in immune 
cells was also seen in young mice, prior to 
the development of obesity, again indicat-
ing a physiological role for T-bet in fat 
distribution (Fig. 1). The proportion of 
Foxp3+ Tregs were, however, increased in 
this depot, consistent with recent reports 
of a potential role for this cell type in insu-
lin sensitivity.6,29 Furthermore, adoptive 
transfer of CD4+ T-bet-deficient T cells 
to young Rag2-deficient mice resulted in 
an enhanced insulin-sensitive phenotype 
with fewer visceral adipose tissue T cells, 
suggesting a key role of T-bet-deficient 
CD4+ T cells in glucose homeostasis. 
Interestingly, T-bet specifies a transcrip-
tional program that imprints the homing 
of T cells to pro-inflammatory sites. We 
have previously shown that the chemokine 
receptor CXCR3 is a direct transcrip-
tional target of T-bet.44,45 Subtle changes 
in the balance of immune cell subtypes 
in adipose tissue may depend, in part, by 
differential expression of chemokines and 
their receptors. We did observe differ-
ences in molecules responsible for T cell 
trafficking in T-bet-deficient mice, such 
as CXCR3 and its ligands compared with 
wild-type mice. These and alterations in 
other trafficking molecules might account 
for the reduced immune cell numbers 
we observed in the visceral adipose tis-
sue depot of T-bet−/− mice. It is likely that 
the subsequent alteration in the immune-
inflammatory environment in adipose 
tissue then impacts on systemic insu-
lin sensitivity. Whether T-bet deficiency 
improves whole body insulin sensitivity 
primarily through alterations in adipose 
tissue immune cell content and cytokine 
secretion remains to be determined. Alter-
ations in leptin, and other adipocytokines 
and soluble mediators, such as free fatty 
acids, have broader effects on metabolism 
by affecting other insulin-sensitive tissues 
such as muscle, the liver, and the brain. 
Whether T-bet deficiency has a direct 
role in these organs, which may then also 
contribute to systemic insulin sensitivity, 
remains to be determined.
The nature and origin of the sig-
nals that trigger the pro-inflammatory 
response in visceral adipose tissue, how-
ever, remains unclear. Naïve T-cell acti-
vation and proliferation requires cognate 
recognition of antigen through a peptide/
MHC (major histocompatability com-
plex) II complex. Our original report that 
leptin able to enhance IFN-γ produc-
tion from T cells has recently been con-
firmed9,13,46 and this has been found to 
induce the expression of MHC II on mac-
rophages and adipocytes.37,46 The expres-
sion of MHC II on adipocytes is an early 
response to obesity. High fat diet fed mice 
deficient for MHC II on adipocytes have 
reduced adipose tissue inflammation and 
are more insulin-sensitive.46 We found 
significant quantitative and qualitative 
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differences between the immune cell and 
cytokine secretion profile of the visceral 
adipose tissue depot and the subcutaneous 
depot in T-bet-deficient mice. Depot dif-
ferences in adipokine expression are well 
recognized47 and are likely to play a role in 
the increased risk of metabolic syndrome 
associated with enhanced visceral adipos-
ity.48 Adipocytes express functional pat-
tern recognition receptors suggesting their 
ability to respond to bacterial and viral 
antigens.49 This may be of relevance to the 
visceral adipose tissue depot in particular 
as it is in close proximity to the gut and 
the intestinal microbiota. Pre-adipocytes 
offer the first line of defense for transloca-
tion of antigens by exhibiting both anti-
microbial and phagocytic activity. Recent 
reports suggest that this depot may be 
in a state of “immune activation” with 
increased expression of MHC class II on 
macrophages and, given the observation 
of a restricted T-cell receptor repertoire, 
that the accumulation of T cells in this 
location may be antigen-driven.5,6 Differ-
ential expression of chemokine receptors 
plays a key part in the process of T-cell 
migration to inflammatory sites, and as 
stated above, T-bet is known to regulate 
molecules that are critical to homing of 
T cells to inflamed sites.8,45 Whether any 
potential inciting antigens are gut-derived 
microbial, or intrinsic adipocyte, in origin 
remains to seen.
Deficiency of T-bet in the immune 
system therefore appears uncouple vis-
ceral adiposity from insulin resistance 
(Fig. 1). This effect appears to be depen-
dent particularly on CD4+ T cells and the 
Th1 signature cytokine IFN-γ and adds 
to the emerging body of data suggesting 
a key role of the adaptive immune system 
in obesity-associated insulin resistance. 
However, T cells are already present fat 
depots prior to the onset of obesity. We 
have found that deficiency of T-bet is 
able to further enhance insulin sensitivity 
even in the lean state. To our knowledge, 
this is the first description of an immune-
restricted molecule directly influencing 
metabolic physiology. A challenge now in 
the emerging field of immunometabolism 
is identification of the downstream molec-
ular interactions through which T-bet is 
able to impact on adiposity and insulin 
action and the potential molecular drivers 
that seem to target this process to the vis-
ceral adipose tissue depot in particular. 
Targeting the T-bet axis may one day offer 
a novel therapeutic strategy in the treat-
ment of conditions associated with insu-
lin resistance, such as obesity and Type 2 
diabetes.
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